Skip to main content
. 2013 Jul 22;6:889–899. doi: 10.2147/OTT.S46301

Figure 1.

Figure 1

Evolution of medical therapy in ovarian cancer with new drugs under investigation.

Abbreviations: EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; MEK, mitogen-activated protein kinase kinase; PIGFab, phosphatidylinositol-glycan biosynthesis class F; FTI, farnesyl transferase inhibitor; CHT, chemotherapy; TLK286, glutathione S-transferase P1-1 activated glutathione analogue; ACA125, murine anti-idiotypic antibody of the tumor-associated antigen CA-125; TAK165, 1−(4−{4−[(2−{(E)−2−[4−(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole; SCH6636, farnesyl protein transferase inhibitor; BMS214662, farnesyltransferase inhibitor.